Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can garlic and enzymes make menopause hormones safer?

NCT ID NCT02618148

Disease control Sponsor: Trieu, Nguyen Thi, M.D. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding natural ingredients like garlic oil and nattokinase to standard hormone replacement therapy (HRT) could reduce the risk of blood clots in menopausal women. The trial involved 60 women divided into premenopausal and postmenopausal groups. Researchers measured how quickly estrogen levels rose to see if the combo was safer than HRT alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hormone replacement therapy (estradiol and progesterone) combined with garlic oil and nattokinase
What this could lead to
If successful, this could point toward a safer way to use hormone therapy for menopause symptoms by lowering the risk of blood clots.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to everyone. The combination's safety and effectiveness need much larger trials to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Jan 2009

Finished

Jun 2015

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in perimenopausal and postmenopausal women. * Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. Exclusion Criteria: * Known, past or suspected breast cancer; * Known or suspected oestrogen-dependent malignant tumours (eg endometrial cancer); * Undiagnosed genital bleeding; * Untreated endometrial hyperplasia; * Previous or current venous thromboembolism (deep venous thrombosis,pulmonary embolism) * Known thrombophilic disorders (eg protein C, protein S, or antithrombin deficiency, see section. * Active or recent arterial thromboembolic disease (eg angina, myocardial infarction); * Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal; * Known hypersensitivity to the active substances or to any of the excipients;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoporosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause

Contacts and locations

Locations

  • Saigon Biopharma Company Limited

    Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.